TrialCirculation2016

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).

C Michael Gibson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.